Paris, France, May 16, 2017
Voisin Consulting Life Science - Paris, France
Voisin Consulting Life Sciences (VCLS) announces the appointment of Carole Jones as Director of Market Access. Ms Jones will focus on expanding the company’s Market Access capabilities, enhancing the variety of services that VCLS already offers. The company’s vision is to support clients to find creative solutions to funding issues and risk sharing strategies, and to manage uncertainty through robust evidence generation. Ms Jones’ responsibilities will span payer strategy, Health Economics and Outcomes Research (HEOR), Health Technology Assessment (HTA) and value communications support. Ms Jones’ extensive experience working directly with NICE and NIHR on HTAs and policy development, as well as her close relationships with various Clinical Commissioning Groups in the UK, Gemeinsamer Bundesausschuss (G-BA) and Haute Autorité de Santé (HAS) in Europe and the Centers for Medicare and Medicaid in the U.S., makes her ideally suited to this position.
‘We at VCLS, are excited about the appointment of Carole Jones and the opportunities it will bring. It further demonstrates our commitment to becoming leaders in product development and commercialization consultation, by offering a well-rounded service to our clients. The extensive experience Carole brings will strengthen our capabilities and put us at the forefront of integrated pharmaceutical development strategy.’ commented Emmanuelle Voisin, Founder and CEO, VCLS.
Ms Jones brings with her a wealth of knowledge and experience from a variety of roles within the healthcare sector. Her career started in the clinical environment and she subsequently gained industry experience working in the commercialization team at QLT (now Novelion Therapeutics), the Canadian biotech company that brought a cutting edge, first-in-class age-related macular degeneration product to market in partnership with Novartis. Ms Jones then transitioned to a global consulting role in IMS Health (now QuintilesIMS) where she was promoted to Practice Leader of the Portfolio Strategy practice and managed the EMEA region for 6 years. Since leaving IMS, Ms Jones has led the Market Access Solutions practice at Envision Pharma Group, a medical affairs company, where she was involved in publication strategy, development of manuscripts and white papers for peer-reviewed journals, systematic literature reviews, global value dossiers and interactive field-based assets.
‘I am delighted to be part of an organization with such an active focus on the integration of payer evidence requirements into the clinical development programs of our clients. The combination of world class regulatory and health economics expertise allows us to be powerful advocates for our clients in navigating the complex, evolving pharmaceutical environment. The goal of delivering innovative therapies and making them accessible to patients is at the forefront of the company’s, and my own, vision.’ said Ms Jones.
Market access has become all the more critical as payer constraints grow. The development of an evidence-based strategy with an expanded value proposition that meets the needs of multiple stakeholders, including patients, is essential to the success of new entrants, never more so than in the area of Advanced Therapy Medicinal Products (ATMPs) where many of our clients are active.
For more information, visit www.voisinconsulting.com
For media enquiries please contact:
Zhengxi Danard - firstname.lastname@example.org or T: +33 1 41 31 83 00